ArticleFrontiers in endocrinology2026
Prevalence and effects on outcomes of intracranial tumors and structural alterations in children with central precocious puberty and early and fast puberty.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate intracranial lesion prevalence in children with central precocious puberty (CPP) and early and fast puberty (EFP), and assess impacts on progression and GnRHa response. Methods: This retrospective study included 1,087 CPP/EFP patients (2011-2023) who underwent brain MRI. Patients were stratified by MRI findings: no lesion, other (incidental) lesions, and pathogenic lesions (hypothalamic hamartoma/glioma). Clinical, hormonal, bone age, and growth parameters were compared. GnRHa dosing and therapeutic responses were evaluated. Results: Intracranial lesions were detected in 14.5% of girls and 19.6% of boys (P = 0.089). Detection was age-dependent: children under specific thresholds (girls <6y, boys <7y) had significantly higher rates than older peers (33.7% vs. 12.1%, P <0.001; 53.8% vs. 16.9%, P = 0.004). Pathogenic lesions (n=26) occurred exclusively in CPP, linked to earlier puberty onset (girls: 1.9y; boys: 1.0y) and elevated luteinizing hormone (LH) levels (P<0.05). Among treated girls (n=312), those with pathogenic lesions required higher 6-month GnRHa doses (P = 0.025) and exhibited faster initial growth velocity (P = 0.007), despite similar hormone suppression and 1-year height SDS changes. Incidental lesions (e.g., Rathke's cysts) did not alter progression or treatment response. Conclusion: Routine MRI is warranted for younger CPP children (girls <6y, boys <7y) due to high pathogenic lesion rates. Conversely, older CPP and all EFP cases show low pathogenic prevalence, questioning universal MRI screening. While incidental lesions require no management alteration, CPP with hypothalamic hamartoma/glioma presents with earlier onset and heightened axis activation, necessitating higher GnRHa doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.